Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN Without a Clinical Response

被引：0

作者：

Panaccione, Remo ^{[1
]}

Abreu, Maria T. ^{[2
]}

Lazariciu, Irina ^{[3
]}

Mundayat, Rajiv ^{[3
]}

Lawendy, Nervin ^{[4
]}

Salese, Leonardo ^{[4
]}

Woolcott, John C. ^{[4
]}

Sands, Bruce E. ^{[5
]}

Chaparro, Maria ^{[6
,7
]}

机构：

[1] Univ Calgary, Cumming Sch Med, Inflammatory Bowel Dis Clin, Gastrointestinal Res, Calgary, AB, Canada

[2] Univ Miami, Miller Sch Med, Crohns & Colitis Ctr, Miami, FL 33136 USA

[3] Pfizer Inc, New York, NY USA

[4] Pfizer Inc, Collegeville, PA USA

[5] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA

[6] Univ Autonoma Madrid, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP, Madrid, Spain

[7] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S761

引用

页码：S351 / S352

页数：2

共 50 条

[31] Long-term treatment with zonisamide: Results of a 2 year open-label extension study
Wroe, S.
Duncan, R.
[J]. EPILEPSIA, 2006, 47 : 138 - 138
[32] Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION study
Ashina, M.
Roos, C.
Ayer, D. W.
Ruff, D.
Krege, J. H.
Li, L. Q.
Komori, M.
[J]. HEADACHE, 2022, 62 : 113 - 114
[33] Long-Term Treatment With Lasmiditan in Patients With Migraine: Results From the Open-Label Extension of the CENTURION Study
Ashina, M.
Roos, C.
Ayer, D.
Ruff, D.
Krege, J.
Li, L. Q.
Komori, M.
[J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
[34] Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
Valenzuela, F.
Korman, N. J.
Bissonnette, R.
Bakos, N.
Tsai, T. -F.
Harper, M. K.
Ports, W. C.
Tan, H.
Tallman, A.
Valdez, H.
Gardner, A. C.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 853 - 862
[35] SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: LONG-TERM DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)
Panaccione, Remo
Lichtenstein, Gary R.
Nakase, Hiroshi
Armuzzi, Alessandro
Kucharzik, Torsten
Levy, Gweneth
Palac, Hannah
Kujawski, Michelle
Klaff, Justin
Cheon, Jae Hee
[J]. GASTROENTEROLOGY, 2023, 164 (06) : S1100 - S1100
[36] Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)
Panaccione, R.
Lichtenstein, G.
Nakase, H.
Armuzzi, A.
Kucharzik, T.
Levy, G.
Palac, H.
Kujawski, M.
Klaff, J.
Cheon, J. H.
[J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 644 - 646
[37] Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders
Rubin, D. T.
Dubinsky, M. C.
Lukas, M.
Quirk, D.
Nduaka, C. I.
Maller, E.
Lawendy, N.
Kayhan, C.
Fan, H.
Woodworth, D. A.
Chan, G.
Su, C.
[J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S51 - S52
[38] LONG-TERM EFFICACY OF TOFACITINIB IN PATIENTS WHO RECEIVED EXTENDED INDUCTION THERAPY: RESULTS OF THE OCTAVE OPEN STUDY FOR TOFACITINIB DELAYED RESPONDERS
Rubin, David T.
Dubinsky, Marla
Lukas, Milan
Quirk, Daniel
Nduaka, Chudy I.
Maller, Eric S.
Lawendy, Nervin
Kayhan, Cem
Fan, Haiyun
Woodworth, Deborah A.
Chan, Gary
Su, Chinyu
[J]. GASTROENTEROLOGY, 2019, 156 (06) : S1102 - S1102
[39] LONG-TERM SPARSENTAN TREATMENT IN FSGS IN THE DUET OPEN-LABEL EXTENSION (OLE)
Trachtman, Howard
Srivastava, Tarak
Tesar, Vladimir
Campbell, Kirk N.
Rheault, Michelle N.
Komers, Radko
Murphy, Edward
Prasad, Andy
Gesualdo, Loreto
[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 81 (04) : S99 - S99
[40] LONG-TERM SPARSENTAN TREATMENT IN YOUNG PATIENTS WITH FSGS IN THE DUET OPEN-LABEL EXTENSION (OLE)
Lieberman, Kenneth
Paredes, Ana
Srivastava, Tarak
Komers, Radko
Murphy, Edward
Prasad, Andy
Trachtman, Howard
[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 81 (04) : S94 - S95

← 1 2 3 4 5 →